

## EDITORIALS



## Coronary Revascularization before Noncardiac Surgery

Mauro Moscucci, M.D., and Kim A. Eagle, M.D.

The evaluation of cardiac risk before noncardiac surgical procedures and interventions aimed toward reducing that risk have become an integral part of the contemporary practice of medicine. In the nonoperative setting, it is generally accepted that the pathophysiology of acute myocardial infarction is usually due to the disruption of a vulnerable coronary-artery plaque followed by coronary-artery thrombosis. Histopathological analyses of coronary arteries in patients who had a fatal myocardial infarction soon after noncardiac surgery have confirmed this pathophysiology, with evidence of an unstable plaque present in more than half of patients.<sup>1</sup>

An association between fatal perioperative myocardial infarction and advanced left main coronary artery disease, severe three-vessel disease, or both is also common. Perioperative activation of neurohumoral pathways, an increase in catecholamine levels, a reduction in endogenous levels of tissue plasminogen activator, an increase in shear stress in association with platelet activation, and possibly coronary spasm have been postulated to be mechanisms leading to plaque disruption and subsequent coronary-artery occlusion. However, some patients appear to have a myocardial infarction without ST-segment elevation, perhaps caused primarily by periods of prolonged ischemia as a result of perioperative stresses that occur in the presence of severe fixed coronary-artery obstruction.

Previous studies have shown that patients at increased risk for perioperative events can be identified on the basis of simple clinical markers (e.g., angina pectoris, previous myocardial infarction, diabetes mellitus, previous heart failure, renal insufficiency, poor functional capacity, or high-risk surgery) available at the time of the initial evaluation.<sup>2,3</sup> The addition of noninvasive and invasive testing

further improves the accuracy of risk stratification.<sup>4</sup> Applying the lessons learned from risk stratification to the care of patients, in an attempt to reduce risk, has been a challenge, particularly in light of the large numbers of patients who currently undergo noncardiac surgery and the variable risks.

There is today overwhelming agreement that aggressive medical management to provide myocardial protection in the perioperative state is a central element in reducing the risk of adverse clinical events. In a landmark clinical trial, patients undergoing noncardiac surgery who had or were at risk for coronary artery disease were randomly assigned to receive atenolol intravenously before and immediately after surgery and orally thereafter for the duration of hospitalization or to receive placebo.<sup>5</sup> A significant reduction in the incidence of perioperative ischemia was observed among the patients who received atenolol. This reduction was associated with a lower mortality in the atenolol group six months after hospital discharge (0 percent, vs. 8 percent in the placebo group;  $P < 0.001$ ), after one year of follow-up (3 percent vs. 14 percent,  $P = 0.005$ ), and after two years of follow-up (10 percent vs. 21 percent,  $P = 0.02$ ). The lower mortality was predominantly due to a reduction in deaths from cardiac causes during the first six to eight months after noncardiac surgery.

Poldermans et al., in the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) trial, investigated the use of the beta-blocker bisoprolol in high-risk patients referred for vascular surgery.<sup>6</sup> In that study, the group treated with bisoprolol had a significant reduction in the incidence of death from cardiac causes as compared with patients receiving standard care (3.4 percent vs. 17 percent,  $P = 0.02$ ) and a significant reduction in the incidence of nonfatal

myocardial infarction (0 percent vs. 17 percent,  $P < 0.001$ ).

The benefits of beta-blockers in these two studies are consistent with the proposed cascade of events that occur when sympathetic activation is triggered by perioperative stresses. Interrupting this cascade, even for a short period of time, might have long-term benefits.

More recently, a large body of data have been reported that support the pleiotropic and antiinflammatory effects of statins, which promote the stabilization of potentially vulnerable coronary plaques and a reduction in adverse coronary events. In particular, the prehospital or preprocedure use of statins has been found to be associated with reductions in the incidence of in-hospital death in patients with acute coronary syndromes, of periprocedural myocardial infarction after percutaneous coronary intervention, and of perioperative mortality in patients undergoing major noncardiac vascular surgery.<sup>7</sup> Although no large, randomized clinical trials have been completed to confirm the efficacy of statins in these settings, the strong association shown in large observational studies supports the inclusion of statins in the perioperative management of patients with known or strongly suspected coronary artery disease who are undergoing noncardiac surgery.

The role of preoperative coronary revascularization in patients being evaluated before noncardiac surgery has been controversial for several decades. The limited size and number of observational studies and the absence of randomized clinical trials have resulted in uncertainty concerning the benefits and risks of preoperative coronary revascularization for the purpose of improving perioperative and longer-term coronary outcomes.

In this issue of the *Journal*, McFalls et al. report the results of the Coronary Artery Revascularization Prophylaxis trial.<sup>8</sup> Patients with clinically significant, stable coronary artery disease who were scheduled for elective vascular operations at 18 Veterans Affairs medical centers were randomly assigned to undergo coronary revascularization (percutaneous coronary intervention or coronary-artery bypass grafting, 258 patients) or medical therapy alone (252 patients). Medical therapy was optimized in both groups, with 84 percent of patients in the revascularization group and 86 percent of those who did not undergo revascularization receiving beta-blockers, 54 percent in both groups receiving statins, and 70 percent and 76 percent,

respectively, receiving aspirin. Patients with a stenosis of the left main coronary artery of at least 50 percent, a left ventricular ejection fraction of less than 20 percent, and severe aortic stenosis were excluded from randomization. The majority of patients enrolled had single-vessel or two-vessel disease. After vascular surgery, there were no differences between the two groups in the incidence of myocardial infarction or in-hospital mortality. At a median follow-up of 2.7 years, the mortality was 22 percent in the revascularization group and 23 percent in the no-revascularization group.

Although the randomized study by McFalls et al. was underpowered to detect differences in event rates in high-risk subgroups, the study design and the clinical question answered put the study at the very top of the list of clinically relevant studies in this field. The results should be interpreted in light of its design, the exclusion criteria, and the ancillary therapies. If one carefully screens candidates for vascular surgery and excludes patients with symptoms of unstable coronary disease, left main coronary artery disease, aortic stenosis, or severe left ventricular dysfunction, and if one provides excellent perioperative medical treatment to those remaining, then coronary revascularization does not appear to provide an additional benefit in reducing the incidence of perioperative death or myocardial infarction. The results mirror those of other randomized clinical trials in the nonoperative setting that have shown that elective coronary revascularization in "low risk" patients who have stable coronary artery disease does not provide a survival benefit and does not reduce the risk of late myocardial infarction as compared with excellent medical and preventive therapies.

However, the issue of whom to screen and how to screen preoperative patients beyond a history taking, physical examination, and preoperative electrocardiography is far from settled. The data reported by McFalls et al. are about therapy for patients with stable, well-defined coronary disease, not screening. There is clearly a tendency to view effective beta-blockade as sufficient to preclude noninvasive screening in most patients being considered for noncardiac surgery, especially in those with known stable coronary disease who are facing lower-risk operations. The DECREASE trial showed a nearly 85 percent reduction in the combined incidence of nonfatal myocardial infarction and death from cardiac causes after elective vascular surgery, owing to effective preoperative, intraoperative, and

postoperative beta-blockade. However, there was a small group of patients with multiple clinical markers of risk and widespread ischemia on preoperative stress echocardiography who were not adequately protected by beta-blockers.<sup>9</sup>

Cost-effective identification of this minority of patients, who have extremely high preoperative risk, is the subject of the American College of Cardiology–American Heart Association guidelines for perioperative cardiovascular evaluation for noncardiac surgery.<sup>2,10</sup> The trial by McFalls and colleagues adds to our foundation of knowledge, answering a critical question about therapy. Now we need a series of additional randomized studies to settle remaining questions about screening and about the value of medical therapies beyond beta-blockade with statins, angiotensin-converting-enzyme inhibitors, antiplatelet agents, and other myocardial protective or vascular stabilizing drugs that are in development.

From the Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Cardiovascular Center, Ann Arbor.

1. Dawood MM, Gupta DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. *Int J Cardiol* 1996;57:37-44.
2. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: re-

port of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 1996;93:1278-317.

3. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999;100:1043-9.
4. Eagle KA, Coley CM, Newell JB, et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. *Ann Intern Med* 1989;110:859-66.
5. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. *N Engl J Med* 1996;335:1713-20. [Erratum, *N Engl J Med* 1997;336:1039.]
6. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. *N Engl J Med* 1999;341:1789-94.
7. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. *Circulation* 2003;107:1848-51.
8. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med* 2004;351:2795-804.
9. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA* 2001;285:1865-73.
10. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation* 2002;105:1257-67.

Copyright © 2004 Massachusetts Medical Society.

## A New Treatment for Ocular Neovascularization

Frederick L. Ferris III, M.D.

Neovascularization leads to blindness in a large number of ocular disorders, most notably age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, and other vascular occlusive diseases. Various versions of scatter-photocoagulation (laser) treatment in the peripheral retina have been shown to reduce the loss of vision that results from retinal vascular diseases but not from age-related macular degeneration.<sup>1-3</sup> For example, scatter photocoagulation, along with vitrectomy when necessary, can reduce the risk of blindness in eyes with retinal neovascularization from diabetic retinopathy by 90 percent.<sup>4</sup> Current treatments for the neovascular complications of age-related macular degeneration are nowhere near this effective, with the result that age-related macular degeneration is the leading cause of blindness in the United States.<sup>5</sup>

Twenty years ago, ophthalmologists were hope-

ful that direct photocoagulation of the neovascularization associated with age-related macular degeneration would prove to be very effective. The short-term results of a clinical trial of this direct ablative treatment showed a reduction by 50 percent in the risk of severe loss of vision.<sup>6</sup> Unfortunately, there were two drawbacks. First, because photocoagulation damages the retina, the treatment was limited largely to areas of neovascularization that did not involve the center of the macula, and thus only about 15 percent of the neovascularization resulting from age-related macular degeneration could be treated. Second, the follow-up data from this five-year trial were much less impressive than the initial results, largely owing to the recurrence of neovascularization, with extension beneath the fovea.<sup>7</sup>

A major advance in our ability to treat the neovascularization associated with age-related macular de-

# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

DECEMBER 30, 2004

VOL. 351 NO. 27

## Coronary-Artery Revascularization before Elective Major Vascular Surgery

Edward O. McFalls, M.D., Ph.D., Herbert B. Ward, M.D., Ph.D., Thomas E. Moritz, M.S., Steven Goldman, M.D., William C. Krupski, M.D.,\* Fred Littooy, M.D., Gordon Pierpont, M.D., Steve Santilli, M.D., Joseph Rapp, M.D., Brack Hattler, M.D., Kendrick Shunk, M.D., Ph.D., Connie Jaenicke, R.N., B.S.N., Lizy Thottapurathu, M.S., Nancy Ellis, M.S., Domenic J. Reda, Ph.D., and William G. Henderson, Ph.D.

### ABSTRACT

#### BACKGROUND

The benefit of coronary-artery revascularization before elective major vascular surgery is unclear.

#### METHODS

We randomly assigned patients at increased risk for perioperative cardiac complications and clinically significant coronary artery disease to undergo either revascularization or no revascularization before elective major vascular surgery. The primary end point was long-term mortality.

#### RESULTS

Of 5859 patients scheduled for vascular operations at 18 Veterans Affairs medical centers, 510 (9 percent) were eligible for the study and were randomly assigned to either coronary-artery revascularization before surgery or no revascularization before surgery. The indications for a vascular operation were an expanding abdominal aortic aneurysm (33 percent) or arterial occlusive disease of the legs (67 percent). Among the patients assigned to preoperative coronary-artery revascularization, percutaneous coronary intervention was performed in 59 percent, and bypass surgery was performed in 41 percent. The median time from randomization to vascular surgery was 54 days in the revascularization group and 18 days in the group not undergoing revascularization ( $P < 0.001$ ). At 2.7 years after randomization, mortality in the revascularization group was 22 percent and in the no-revascularization group 23 percent (relative risk, 0.98; 95 percent confidence interval, 0.70 to 1.37;  $P = 0.92$ ). Within 30 days after the vascular operation, a postoperative myocardial infarction, defined by elevated troponin levels, occurred in 12 percent of the revascularization group and 14 percent of the no-revascularization group ( $P = 0.37$ ).

#### CONCLUSIONS

Coronary-artery revascularization before elective vascular surgery does not significantly alter the long-term outcome. On the basis of these data, a strategy of coronary-artery revascularization before elective vascular surgery among patients with stable cardiac symptoms cannot be recommended.

From the Minneapolis Veterans Affairs (VA) Medical Center (E.O.M., H.B.W., G.P., S.S., C.J.) and the Department of Medicine, Division of Cardiology (E.O.M., G.P.), and the Department of Surgery (S.S.), Division of Cardiovascular and Thoracic Surgery (H.B.W.), University of Minnesota — all in Minneapolis; the Cooperative Studies Program Coordinating Center (T.E.M., L.T., N.E., D.J.R.) and the Division of Peripheral Vascular Surgery (F.L.), VA Medical Center, Hines, Ill.; Southern Arizona VA Health Care System and the University of Arizona Sarver Heart Center — both in Tucson (S.G.); the Denver VA Medical Center, Denver (W.C.K., B.H.); the Department of Surgery (J.R.) and the Division of Cardiology (K.S.), University of California, San Francisco; San Francisco VA Medical Center, San Francisco (J.R., K.S.); and the University of Colorado Health Outcomes Program, Aurora, and the Department of Preventive Medicine and Biometrics, University of Colorado, Denver (W.G.H.). Address reprint requests to Dr. McFalls at the Division of Cardiology, VA Medical Center, 1 Veterans Dr., Minneapolis, MN 55417, or at [mcfall001@tc.umn.edu](mailto:mcfall001@tc.umn.edu).

\*Deceased.

N Engl J Med 2004;351:2795-804.

Copyright © 2004 Massachusetts Medical Society.

**T**HE OPTIMAL TREATMENT OF PATIENTS undergoing elective vascular surgery has not been clearly defined. Because the prevalence of coronary artery disease among these patients approaches 50 percent,<sup>1</sup> the incidence of perioperative cardiac complications is high, leading to a rigorous process of risk stratification.<sup>2-5</sup> In the absence of any outcome-based studies, panels of experts have recommended that preoperative coronary-artery revascularization be reserved for subgroups of patients with unstable cardiac symptoms or for whom coronary-artery bypass grafting (CABG) offers a long-term survival benefit.<sup>6,7</sup> Despite these published guidelines, there is substantial variability among clinicians concerning the recommendations for preoperative cardiac intervention,<sup>8</sup> which reflects in part, the absence of any randomized studies.

In support of the aggressive treatment of coronary artery disease before vascular surgery, retrospective data indicate that revascularization improves long-term outcomes.<sup>9</sup> In addition, among the cohort of patients from the Coronary Artery Surgery Study with peripheral vascular disease, the survival after 3.5 years in the surgically treated group was better than that in the group receiving medical therapy.<sup>10</sup> In support of a conservative management plan, retrospective data from a large registry of patients who had undergone vascular surgery show that procedure-related complications among patients undergoing preoperative revascularization are frequent, often leading to critical delays in the intended vascular surgery.<sup>11</sup> Therefore, we undertook the Coronary Artery Revascularization Prophylaxis (CARP) trial to assess the long-term benefit of preoperative coronary-artery revascularization among patients with stable coronary artery disease who are scheduled for elective vascular surgery.

## METHODS

### STUDY PATIENTS

Patients were eligible for the study if they were scheduled for an elective vascular operation for either an expanding abdominal aortic aneurysm or severe symptoms of arterial occlusive disease involving the legs. The exclusion criteria were a need for urgent or emergency surgery, a severe coexisting illness, or prior revascularization without evidence of recurrent ischemia.<sup>12</sup>

Coronary angiography was recommended for eligible patients if the patient was considered by a

cardiology consultant to be at increased risk for a perioperative cardiac complication. Guidelines for coronary angiography were provided for each site on the basis of combined clinical risk factors and the presence or absence of ischemia on a noninvasive stress imaging study.<sup>4</sup> During the study, cardiology consultants were also influenced by other recognized risk factors including a prior stroke, insulin-dependent diabetes, and renal failure,<sup>13</sup> as well as by a greater reliance on stress imaging.<sup>14</sup>

On the basis of the coronary angiogram, a patient was eligible for the study if one or more major coronary arteries had a stenosis of at least 70 percent and were suitable for revascularization. Local investigators decided which revascularization procedure to use, either percutaneous coronary intervention or CABG. Although percutaneous coronary intervention and CABG are considered equivalent before major noncardiac operations,<sup>15</sup> the potential long-term advantage of CABG among patients with diabetes and multivessel disease was recognized.<sup>16</sup> Anatomical exclusion criteria were a stenosis of the left main coronary artery of at least 50 percent, a left ventricular ejection fraction of less than 20 percent, and severe aortic stenosis.

Study patients were recruited for a 12-month feasibility trial (from August 1997 through July 1998) involving five Veterans Affairs (VA) medical centers. Enrollment for the main study, involving 18 VA medical centers, occurred from March 1999 through February 2003. As planned, the efficacy results from the pilot study were not evaluated at its completion so that they could be combined with the results of the main study. Follow-up ended on February 28, 2004. The human rights committee of the VA Cooperative Studies Program and the institutional review board at each participating VA medical center approved the study.

### RANDOMIZATION AND TREATMENT

We used a stratified randomization process with permuted blocks. The stratification factors were the hospital and, because intraabdominal and infrainguinal operations have different outcomes, the proposed vascular surgery.<sup>17</sup> After randomization, we expected the intended procedure (either cardiac or vascular) to be performed within three weeks. If CABG was planned, we expected the vascular operation to occur within three months. If percutaneous coronary intervention was planned, we expected the vascular operation to be delayed for at least two weeks, owing to an increased risk of an in-stent cor-



onary-artery thrombus.<sup>18</sup> For three days after vascular surgery, blood was collected and sampled for cardiac enzymes and an electrocardiogram was obtained. Three months after surgery, the left ventricular ejection fraction was determined with the use of radionuclide angiography. All patients who underwent randomization had follow-up visits at the local site every three months for the first year and every six months for the remainder of the study.

#### OUTCOMES

The primary end point was long-term mortality and was ascertained through follow-up and by means of the Veterans Affairs Beneficiary Identification and Records Locator Subsystem. Secondary end points included myocardial infarction, stroke, limb loss, and dialysis. Eighty-six percent of patients in the revascularization group and 85 percent of patients in the no-revascularization group had follow-up visits within one year before the end of the study. After revascularization (CABG or percutaneous coronary intervention), myocardial infarction was diagnosed on the basis of a combination of elevated levels of cardiac enzymes and changes in the electrocardiogram. A myocardial infarction after the vascular surgery was diagnosed on the basis of elevated levels of cardiac enzymes and was characterized by associated ischemic changes on the electrocardiogram. The end-points committee, which was independent of the study and blinded to the assigned treatment, validated all outcomes.

#### STATISTICAL ANALYSIS

We predicted mortality on the basis of the outcomes of patients from the Coronary Artery Surgery Study registry who had peripheral vascular disease.<sup>10</sup> A 5 percent one-sided log-rank test was used, indicating that a sample of 559 patients would be needed to provide the study with 90 percent power to detect differences in the 3.5-year survival rates of 75 percent in one group and 85 percent in the other. Because recruitment was slower than expected in the main study, the three-year enrollment period, with a minimal follow-up of two years, was changed to a four-year enrollment period, with a one-year follow-up. Total recruitment was 510 patients (of whom 98 percent were male), who were randomly assigned to one of the two study groups.

Intention-to-treat analyses provided information about survival, from the time of randomization. Survival curves were generated with the use of Kaplan-Meier product-limit estimates, and intergroup dif-

ferences were evaluated by the log-rank test. The Cox proportional-hazards model was used to calculate estimates of relative risk and 95 percent confidence intervals, comparing treatments within high-risk subgroups of patients. Data are expressed as means  $\pm$ SD, or as medians with interquartile range when specified. All tests were two-sided.

## RESULTS

#### SCREENING

Of 5859 patients scheduled for vascular surgery, 4669 (80 percent) were initially excluded. The main reasons were insufficient cardiac risk (1654 patients), an urgent need for vascular surgery (1025), prior CABG or percutaneous coronary intervention without ischemia (626), and a severe coexisting illness (731). The patient's decision not to participate and ineligibility because of participation in other research studies accounted for 633 exclusions. Of the patients who underwent coronary angiography without any clinical exclusions, 680 were excluded for reasons that were specified in the protocol. The primary reason was either nonobstructive coronary arteries (363 patients) or coronary artery disease that was not considered amenable to successful revascularization (215). Other anatomical reasons for exclusion included a stenosis of the left main coronary artery of at least 50 percent (54 patients), a left ventricular ejection fraction of less than 20 percent (11), and severe aortic stenosis (8). Refusal to participate, by either the patient or the referring physician, accounted for 29 exclusions.

#### STUDY PATIENTS

Of the 510 patients (9 percent of the 5859 originally screened) who underwent randomization, 258 were assigned to a strategy of preoperative coronary-artery revascularization, and 252 to no revascularization. There were no significant differences in the baseline characteristics of the two groups (Table 1). According to the criteria of Eagle and colleagues regarding preoperative assessment of cardiac risk,<sup>4</sup> 28 percent had three or more clinical risk factors, and 65 percent had either three or more clinical risk factors or one or two risk factors with ischemia, as demonstrated on a stress test. According to the Revised Cardiac Risk Index, 49 percent had two or more risk factors, and 13 percent had three or more risk factors.<sup>13</sup> Nuclear stress imaging was performed in 316 (62 percent) of the study patients. The size of the reversible defect relative to total my-

**Table 1. Baseline Clinical Variables According to the Assigned Treatment before the Elective Major Vascular Surgery.\***

Variable	Revascularization (N=258)	No Revascularization (N=252)	P Value
Age — yr	65.6±11.1	67.2±10.4	0.10
Angina — no. (%)	103 (39.9)	95 (37.7)	0.61
Previous myocardial infarction — no. (%)	111 (43.0)	103 (40.9)	0.62
Previous congestive heart failure — no. (%)	31 (12.0)	19 (7.5)	0.09
Previous stroke or TIA — no. (%)	54 (20.9)	47 (18.7)	0.50
Diabetes — no. (%)			
Treated with oral agents	49 (19.0)	52 (20.6)	0.84
Treated with insulin	48 (18.6)	49 (19.4)	0.84
Current smoker — no. (%)	128 (49.6)	114 (45.2)	0.41
Albumin — g/dl	3.7±0.6	3.7±0.5	0.99
Hemoglobin — g/dl	14.0±2.4	13.8±1.9	0.26
Total cholesterol — mg/dl	175±45	182±51	0.13
LDL cholesterol — mg/dl	105±37	107±42	0.60
HDL cholesterol — mg/dl	37±10	37±11	0.95
Glycosylated hemoglobin — %	6.6±1.7	6.8±1.9	0.41
C-reactive protein — mg/dl			0.12
Median	0.4	0.3	
Interquartile range	0.05–1.4	0.04–1.3	
Homocysteine — mg/dl			0.63
Median	10.3	9.8	
Interquartile range	0.8–13.6	0.3–12.8	
Left ventricular ejection fraction — %	54±12	55±12	0.36
Three-vessel coronary artery disease — no. (%)	91 (35.3)	79 (31.3)	0.69
Previous CABG — no. (%)	38 (14.7)	39 (15.5)	0.83
Indication for surgery†			0.61
Abdominal aneurysm — no. (%)	88 (34.1)	81 (32.1)	—
Claudication — no. (%)	100 (38.8)	89 (35.3)	—
Pain at rest — no. (%)	30 (11.6)	35 (13.9)	—
Tissue breakdown — no. (%)	40 (15.5)	47 (18.7)	—

\* Plus-minus values are means ±SD. TIA denotes transient ischemic attack, LDL low-density lipoprotein, and HDL high-density lipoprotein. To convert the values for hemoglobin to millimoles per liter, multiply by 0.6206. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

† A single P value is provided for the entire group (two-by-four chi-square test with three degrees of freedom). A dash denotes not applicable.

ocardial perfusion was determined at each site and graded semiquantitatively as small, moderate, or large. The size of the perfusion defect was moderate or large in 226 patients. Overall, 74 percent of the study patients had three or more of the Eagle clinical criteria, two or more variables defined by the Revised Cardiac Risk Index, or a moderate or large reversible defect on stress imaging. In the majority

of the remaining patients, angina or abnormal results on the stress test were the reason for preoperative coronary angiography.

**CORONARY-ARTERY REVASCULARIZATION**

Of the 258 study patients assigned to preoperative coronary-artery revascularization, 240 (93 percent) underwent either CABG (99 patients) or percutane-

ous coronary intervention (141 patients). Of the 18 patients who did not undergo preoperative revascularization, 8 (3 percent) required urgent vascular surgery and 9 (3 percent) chose not to undergo revascularization. In one patient, a stroke precluded proceeding with the scheduled CABG. Table 2 summarizes the results for the 240 patients who underwent CABG or percutaneous coronary intervention as part of the assigned treatment. Of four deaths associated with revascularization, two deaths in the percutaneous-coronary-intervention group and one death in the CABG group occurred after successful revascularization and shortly after vascular surgery. Those three deaths were considered complications of revascularization because they occurred during the same hospitalization period.

After randomization, 9 of the 252 patients assigned to undergo no revascularization before vascular surgery (4 percent) required preoperative revascularization because of an unstable change in cardiac status. Seven of them subsequently underwent vascular surgery after revascularization.

#### VASCULAR SURGERY

Of the 258 patients assigned to undergo preoperative revascularization, 225 (87 percent) underwent the planned vascular operation, as did 237 of the 252 patients (94 percent) assigned to no preoperative revascularization. Of the 33 patients randomly assigned to revascularization who did not undergo vascular surgery, 10 died after uncomplicated CABG or percutaneous coronary intervention, 18 declined the surgery (5 on the advice of the primary physician), and a severe coexisting condition developed in 5. Of the 15 patients randomly assigned to no preoperative revascularization who did not undergo vascular operation, 1 died after urgent CABG, 9 declined (3 on the advice of the primary physician), and a severe coexisting condition developed in 5. Among the patients who underwent vascular surgery, there was a significantly longer time to vascular surgery in the group assigned to revascularization than in the group assigned to no revascularization. In the group assigned to revascularization, the vascular operation occurred a median of 48 days after CABG and 41 days after percutaneous coronary intervention. There were no other intergroup differences in perioperative management (Table 3). With the exception of the use of intravenous nitroglycerin, there were no significant differences in perioperative medications.

**Table 2. Procedural Characteristics and Postprocedural Complications of CABG and Percutaneous Coronary Intervention (PCI) in 240 Patients Assigned to Undergo Coronary-Artery Revascularization before Elective Major Vascular Surgery.\***

Characteristic	CABG (N=99)	PCI (N=141)
Days since randomization		
Median	18	1
Interquartile range	7–34	0–7
Urgent or emergency cardiac status — no. (%)	2 (2.0)	1 (0.7)
No. of vessels revascularized	3.0±0.8	1.3±0.8
Completeness of revascularization — %†	98.0	61.9
Death — no. (%)‡	2 (2.0)	2 (1.4)
Myocardial infarction — no. (%)	7 (7.1)	7 (5.0)
Stroke, loss of leg, or renal dialysis — no.	0	0
Reoperation — no. (%)	6 (6.1)	NA
Urgent CABG — no. (%)	NA	1 (0.7)
Days in hospital after procedure		
Median	7	1
Interquartile range	5–12	1–2

\* Plus-minus values are means ±SD. NA denotes not applicable.

† Completeness of revascularization indicates the percentage of major epicardial vessels with stenosis of more than 70 percent that were revascularized.

‡ One of the deaths in the CABG group and the two in the PCI group occurred within two weeks of the revascularization and after the vascular operation. They are listed as complications of both the revascularization and the vascular procedures, because they occurred within the same hospitalization period. Myocardial infarction associated with CABG or PCI was defined by cardiac-enzyme elevations and ischemic changes on the electrocardiogram.

#### POSTOPERATIVE OUTCOMES

Before vascular surgery, there were 10 deaths in the revascularization group and 1 death in the no-revascularization group. Within the 30-day period after the vascular surgery, there were seven deaths (3 percent) in the revascularization group and eight deaths (3 percent) in the no-revascularization group (Table 3). Two of the deaths in the revascularization group occurred in patients who had undergone successful percutaneous coronary intervention but required urgent vascular surgery seven days later. The core laboratory for measurement of cardiac enzymes received blood samples from 88 percent of the patients, and a postoperative myocardial infarction, defined by elevated troponin levels, occurred in 16 percent of those patients; this rate is consistent with the percentage of myocardial infarctions recorded for all patients at the individual sites (Table 3).



**Table 3. Clinical Features and Outcomes of Vascular Surgery According to the Assigned Treatment before the Elective Major Vascular Surgery.**

Characteristic	Revascularization (N=225)	No Revascularization (N=237)	P Value
<b>Surgical management</b>			
Abdominal surgery — no. (%) <sup>*</sup>	89 (39.9)	99 (42.1)	0.89
Urgent or emergency status — no. (%)	13 (5.8)	14 (5.9)	0.90
General anesthesia — no. (%)	180 (80.0)	199 (84.0)	0.50
Altered surgical procedure — no. (%) <sup>†</sup>	33 (14.7)	27 (11.4)	0.30
Days after randomization			<0.001
Median	54	18	
Interquartile range	28–80	7–42	
<b>Perioperative medications — no. (%)</b>			
Beta-adrenergic blockers	188 (83.6)	204 (86.1)	0.45
Aspirin <sup>‡</sup>	168 (76.7)	165 (70.2)	0.12
Statins <sup>§</sup>	121 (53.8)	122 (54.0)	0.93
Heparin <sup>*</sup>	209 (93.7)	219 (93.2)	0.82
Intravenous nitroglycerin	63 (28.0)	87 (36.7)	0.05
<b>Postoperative events (within 30 days)</b>			
Death — no. (%)	7 (3.1)	8 (3.4)	0.87
<b>Myocardial infarction<sup>¶</sup></b>			
Enzymes — no. (%)	26 (11.6)	34 (14.3)	0.37
Enzymes and ECG — no. (%)	19 (8.4)	20 (8.4)	0.99
Stroke — no. (%)	1 (0.4)	2 (0.8)	0.59
Loss of leg — no. (%)	1 (0.4)	5 (2.1)	0.11
Renal dialysis — no. (%)	1 (0.4)	1 (0.4)	0.97
Reoperation — no. (%)	17 (7.6)	18 (7.6)	0.99
Total days in the intensive care unit			0.25
Median	2.0	2.0	
Interquartile range	1–3	1–4	
Total days in the hospital			0.29
Median	6.5	7.0	
Interquartile range	4–10	5–12	

<sup>\*</sup> No information was available for two patients in each group.

<sup>†</sup> An altered surgical procedure refers to a surgical procedure (abdominal or infrainguinal) that differed from the projected surgical procedure that was planned before randomization.

<sup>‡</sup> No information was available for six patients in the revascularization group and two in the no-revascularization group.

<sup>§</sup> No information was available for 11 patients in the no-revascularization group.

<sup>¶</sup> Myocardial infarction was defined by any elevation in cardiac enzymes after surgery, as well as by any elevation in cardiac enzymes with ischemic changes on the electrocardiogram (ECG).

#### LONG-TERM OUTCOME

Three months after vascular surgery, the left ventricular ejection fraction was 54±13 percent in the revascularization group and 55±12 percent in the no-revascularization group (P=0.69). The median follow-up time for mortality was 2.8 years (inter-

quartile range, 1.7 to 3.9) in the revascularization group and 2.6 years (interquartile range, 1.6 to 3.8) in the no-revascularization group. There were 137 deaths (70 in the revascularization group and 67 in the no-revascularization group). At a median of 2.7 years after randomization, mortality was 22 percent


in the revascularization group and 23 percent in the no-revascularization group (relative risk, 0.98; 95 percent confidence interval, 0.70 to 1.37;  $P=0.92$ ) (Fig. 1). Among the patients assigned to no preoperative coronary-artery revascularization, 21 (8 percent) underwent postoperative coronary-artery revascularization after vascular surgery. When the analysis was repeated according to treatment received rather than treatment assigned at randomization, the rate of death at 2.7 years was 22 percent of the patients who underwent revascularization (249 patients) and 23 percent of the patients who did not undergo revascularization (261 patients) (relative risk, 0.97; 95 percent confidence interval, 0.69 to 1.36;  $P=0.86$ ).

A Cox regression model used to analyze subgroups of patients with characteristics indicating a high risk showed that coronary-artery revascularization did not impart a survival benefit in any of the high-risk subgroups (Table 4). Beta-blockers, antiplatelet agents (aspirin or inhibitors of adenosine diphosphate), angiotensin-converting-enzyme inhibitors, and statins were used by the vast majority of patients 24 months after randomization, and their use did not differ between the groups (Fig. 2).

## DISCUSSION

The principal finding of this cooperative study at 18 VA medical centers is that, among patients with stable coronary artery disease, coronary-artery revascularization before elective major vascular surgery does not improve long-term survival. Although the study was not designed to test the short-term benefit of prophylactic revascularization, there was also no reduction in early postoperative outcomes, including death, myocardial infarction, and length of the hospital stay. The findings support the opinions of the task force of the American College of Cardiology and the American Heart Association and of the American College of Physicians, which have recommended that CABG or percutaneous coronary intervention be reserved for patients with unstable cardiac symptoms or advanced coronary artery disease, for whom a survival benefit with CABG has been proved.<sup>6,7</sup> Despite these published guidelines, there is a lack of consensus among cardiologists regarding the indications for preoperative coronary-artery revascularization,<sup>8</sup> which probably reflects the absence of published data.

The results reported here differ from the findings of the prospectively designed Coronary Artery



**Table 4. Influence of Coronary-Artery Revascularization on Long-Term Survival among High-Risk Subgroups of Patients Scheduled for Vascular Surgery.\***


High-Risk Variable	Patients (N=510) no. (%)	Hazard Ratio (95% CI)	P Value
Angina	198 (38.8)	1.45 (0.79–2.64)	0.23
Positive stress imaging test†	226 (44.3)	1.26 (0.77–2.06)	0.35
Fulfillment of criteria of Eagle and colleagues‡	142 (27.8)	0.90 (0.51–1.62)	0.73
With large stress-induced defect	37 (7.3)	3.96 (0.82–19.11)	0.09
Category of revised Cardiac Risk Index‡§	248 (48.6)	1.20 (0.76–1.89)	0.44
With large stress-induced defect	50 (9.8)	1.65 (0.64–4.25)	0.30
Prior CABG	77 (15.1)	1.81 (0.81–4.05)	0.15
Three-vessel disease and left ventricular dysfunction	74 (14.5)	1.29 (0.62–2.65)	0.50
Pain at rest and tissue breakdown	152 (29.8)	0.76 (0.43–1.34)	0.34

\* CI denotes confidence interval.

† The stress imaging test refers to a moderate or large reversible defect.

‡ The criteria include at least three of the following clinical risk factors: an age greater than 70 years, previous myocardial infarction, Q waves on an electrocardiogram, previous congestive heart failure, previous ventricular tachycardia, angina, or diabetes mellitus.

§ The index includes at least two of the following clinical risk factors: prior stroke or transient ischemic attack, congestive heart failure, coronary artery disease (excluding previous coronary-artery revascularization), a serum creatinine concentration greater than 2.0 mg per deciliter (177  $\mu$ mol per liter), insulin-dependent diabetes mellitus, or a suprainguinal operation.



Surgery Study, which showed a survival benefit associated with CABG among patients with severe vascular disease.<sup>10</sup> It is unlikely that our failure to demonstrate a long-term benefit with revascularization was a result of procedural complications. The mortality and morbidity associated with CABG and percutaneous coronary intervention in this trial were lower than that in previous reports involving prophylactic revascularization before vascular surgery<sup>11</sup> and are more consistent with the expected rates in a general medical population.<sup>19</sup> It is also unlikely that our trial failed to detect differences in treatment because of insufficient power. Although enrollment was 9 percent lower than the target sample size and the minimal follow-up was slightly reduced, the follow-up in the patients from the pilot study was longer than expected, and the actual number of deaths in the trial was higher than expected. Therefore, the power of this study, recalculated at a two-sided  $\alpha$  level of 0.05, was 90 percent, showing no net loss of power.

We believe our findings can be generalized to a large group of male patients who are considered at increased risk for cardiac complications of elective vascular surgery. Before patients were enrolled in our study, a cardiology consultant at each site ini-

tially screened all patients and recommended coronary angiography on the basis of his or her interpretation of the cardiac risk. Analysis of the baseline data showed that at least 74 percent of the study patients would have been considered to be at least at intermediate risk because of either clinical criteria<sup>4,13</sup> or results from noninvasive imaging tests showing a high risk.<sup>14</sup> The majority of the remaining patients were considered to be at risk because of either an abnormal stress test or the presence of angina, which has been shown to be a risk factor.<sup>20</sup> Although the results may help guide preoperative therapy for a broad group of patients with stable cardiac symptoms, they cannot be extrapolated to all patients in need of vascular surgery, particularly those with unstable angina, aortic stenosis, or severe left ventricular dysfunction.

The potential effect of advances in medical therapy since the Coronary Artery Surgery Study cannot be overemphasized. The widespread use of beta-blockers, antiplatelet agents, angiotensin-converting-enzyme inhibitors, and statins in our study population throughout the follow-up period may have improved the outcomes in all patients and diminished the differences in long-term survival between those treated according to an initial aggressive preoperative strategy and those treated according to a conservative strategy. Moreover, in the perioperative period, beta-adrenergic-blocking agents, which have been demonstrated to improve outcomes among patients undergoing vascular surgical procedures,<sup>21,22</sup> were judiciously administered to most study patients. This treatment, as well as the use of statins, may have adequately protected the medical therapy group at the time of the vascular surgery.

The intense perioperative management by the study investigators may also have influenced favorably the outcome of the patients who did not undergo revascularization. This management included the perioperative care by the anesthesiologists and surveillance by the vascular surgical team in the early postoperative period. With staff available 24 hours a day in the catheterization laboratory to intervene if necessary, patients with acute coronary syndromes in the present era may have an improved postoperative prognosis. The incidence of postoperative myocardial infarctions was not reduced by coronary interventions, suggesting that the mechanism of cardiac-enzyme release after vascular surgery involves more complex mechanisms than the number of coronary arteries with critical stenoses. There is

emerging evidence that postoperative myocardial infarctions are commonly associated with disease progression in vessels with minimal stenosis.<sup>23</sup> Incomplete revascularization could be a factor in the lack of protection against postoperative myocardial infarctions, but the completeness of both percutaneous coronary intervention and CABG in the present study were similar to those in previous studies.<sup>16</sup>

In conclusion, this multicenter, randomized trial shows that coronary-artery revascularization before elective vascular surgery does not alter long-term

survival. Although the study was not powered to detect a beneficial effect in the short term, there also appears to have been no reduction in the number of postoperative myocardial infarctions, deaths, or days in the hospital. On the basis of these data, coronary-artery revascularization before elective vascular surgery among patients with stable cardiac symptoms cannot be recommended.

Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development.

This article is dedicated to the memory of William C. Krupski.

#### APPENDIX

Organizational members of the Coronary Artery Revascularization Prophylaxis trial were as follows: *Site Investigators* — M. Icenogle, M. Langsfeld, S. Pett (Albuquerque, N.M.); K. Mavromatis, A.A. Salam, J.D. Vega (Atlanta); J. Jean-Claude, G. Pinault, J. Ortiz (Cleveland); P. Frenkel, M. Jessen, J.G. Modrall (Dallas); W. Krupski, B. Hattler (Denver); J. Gray, K. Morris, W. Wolfe (Durham, N.C.); R. Kerensky, S. Lind, M. Staples (Gainesville, Fla.); A. Greene, S. Lalka, T. Sharp (Indianapolis); M. Moursi, Y.W. Aude, T. Antakli (Little Rock, Ark.); G. Pierpont, S. Santilli (Minneapolis); S. Muluk, F. Sonel, M. Zenati (Pittsburgh); J. Edwards, G. Larsen, P. Ravichandran (Portland, Oreg.); G. Chilton, E. Sako, M. Sykes, B. Toursarkissian (San Antonio, Tex.); J. Rapp, M. Ratcliffe, K. Shunk (San Francisco); T.R. Kohler, K. Lehmann (Seattle); M. Back, D. Novitzky, M.A. Siddique (Tampa, Fla.); S. Goldman, G. Sethi, A. Westerband (Tucson, Ariz.); D. Baker, R. Ebrahimi, F. Esmailian, B. Singh (West Los Angeles); D. DePinto, F. Littooy, H. Loeb (Hines, Ill.); T. Gavin, K.B. Ramanathan, D. Weiman (Memphis, Tenn.); S. Khuri, G. Sharma (West Roxbury, Mass.); *End-Point Committee* (confirmed end points on the basis of pertinent hospital records) — K. Weir, R. Kelly, J. Davenport; *Cooperative Studies Program Coordinating Center*, Hines, Ill. — N. Ellis, T. Moritz, W. Henderson, D. Reda, L. Thottapurathu; *Clinical Coordinator* — C. Jaenicke; *Angiography Core Laboratory* (reviewed all angiograms) — K. Weir; *Specimen Testing Core Laboratory* (validated perioperative cardiac enzymes) — F. Apple (Hennepin County Medical Center, Minneapolis); *Good Clinical Practice* — C. Haakenson; *Study Coordinators* — D. Robertson (Albuquerque, N.M.); D. House (Atlanta); G. Webbs (Cleveland); A. Swann (Dallas); W. Klenke (Denver); K. Swails (Durham, N.C.); J. Brown (Gainesville, Fla.); M. Rusomarov (Indianapolis); R. Pacheco (Little Rock, Ark.); J. Weigenan, (Minneapolis); M. DiTommaso (Pittsburgh); S. Perez (San Francisco); A. Sorley (Seattle); A. Esquivel (San Antonio, Tex.); S. Thomas (Tampa, Fla.); A. Morgan, K. Zadina (Tucson, Ariz.); L. Cole (West Los Angeles); J. Maggio (Hines, Ill.); R. Thomas (Memphis, Tenn.); J. Bannister (West Roxbury, Mass.); *Executive Committee* — E. McFalls (Chair), H. Ward (Co-Chair), C. Jaenicke, T. Moritz, S. Goldman, W. Krupski, F. Littooy, D. Reda; *Data and Safety Monitoring Board* — N. Hertzler, B.J. Gersh, F. Grover, R. Chappell.

#### REFERENCES

- Hertzler NR, Young JR, Kramer JR, et al. Routine coronary angiography prior to elective aortic reconstruction: results of selective myocardial revascularization in patients with peripheral vascular disease. *Arch Surg* 1979;114:1336-44.
- Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Engl J Med* 1977;297:845-50.
- Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. *J Gen Intern Med* 1986;1:211-9.
- Eagle KA, Coley CM, Newell JB, et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. *Ann Intern Med* 1989;110:859-66.
- Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med* 1992;326:381-6.
- American College of Physicians. Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. *Ann Intern Med* 1997;127:309-12.
- Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *J Am Coll Cardiol* 2002;39:542-53.
- Pierpont G, Moritz T, Goldman S, et al. Disparate opinions regarding indications for coronary artery revascularization prior to elective vascular surgery. *Am J Cardiol* 2004;94:1124-8.
- Hertzler NR, Young JR, Bevern EG, et al. Late results of coronary bypass in patients with peripheral vascular disease. II. Five-year survival according to sex, hypertension, and diabetes. *Cleve Clin J Med* 1987;54:15-23.
- Rihal CS, Eagle KA, Mickel MC, Foster ED, Sopko G, Gersh BJ. Surgical therapy for coronary artery disease among patients with combined coronary artery and peripheral vascular disease. *Circulation* 1995;91:46-53.
- Mesh CL, Cmolik BL, Van Heekeren DW, et al. Coronary bypass in vascular patients: a relatively high-risk procedure. *Ann Vasc Surg* 1997;11:612-9.
- McFalls EO, Ward HB, Krupski WC, et al. Prophylactic coronary artery revascularization for elective vascular surgery: study design. *Control Clin Trials* 1999;20:297-308.
- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999;100:1043-9.
- Shaw LJ, Eagle KA, Gersh BJ, Miller DD. Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery. *J Am Coll Cardiol* 1996;27:787-98.
- Hassan SA, Hlatky MA, Boothroyd DB, et al. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Med* 2001;110:260-6.
- The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;335:217-25. [Erratum, *N Engl J Med* 1997;336:147.]
- Krupski WC, Layug EL, Reilly LM, Rapp JH, Mangano DT. Comparison of cardiac morbidity between aortic and infrainguinal operations. *J Vasc Surg* 1992;15:354-65.
- Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of

- noncardiac surgery soon after coronary stenting. *J Am Coll Cardiol* 2000;35:1288-94.
19. Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery bypass surgery: survival data. *Circulation* 1983;68:939-50.
20. McFalls EO, Doliszny KM, Grund F, Chute E, Chesler E. Angina and persistent exercise thallium defects: independent risk factors in elective vascular surgery. *J Am Coll Cardiol* 1993;21:1347-52.
21. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. *N Engl J Med* 1996;335:1713-20. [Erratum, *N Engl J Med* 1997;336:1039.]
22. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. *N Engl J Med* 1999;341:1789-94.
23. Ellis SG, Hertzner NR, Young JR, Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. *Am J Cardiol* 1996;77:1126-8.

*Copyright* © 2004 Massachusetts Medical Society.